glp-1 drugs canada Health approves first pill for high-risk type 2 diabetes patients Canada greenlights first daily GLP-1
Description
Introduced around the 2000s, these drugs have opened new avenues in weight management strategies, heralding a paradigm shift in obesity treatment
Individuals have a higher risk of gaining the weight back if they do not keep up with the healthy lifestyle changes they made
In consideration of the reduced compliance of peptide GLP-1 receptor agonists due to subcutaneous injection, oral micromolecular GLP-1 receptor agonists such as orforglipron have already in clinical trials, which can reduce body weight and improve cardiac metabolism in adults with obesity (Wharton et al 2023) (Fig
Front Immunol 14:1148209
About Us Careers Partner with us Forgot password
2023 January;22(1):20-27 | doi: 10.12788/cp.0318 Evidence suggests substantial beneficial effects on weight and glycemic dysregulation
